UP!

TNDM $60.19

TNDM target price
60.19
0
0
Tandem Diabetes Care, Inc.
Type
Public
Traded as NASDAQ: TNDM
Founded San Diego, California 2006 (2006)
Headquarters San Diego, California, United States
Number of employees
437
Website www.tandemdiabetes.com

Tandem Diabetes Care is a public US medical device manufacturer based in San Diego, CA. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.

In 2006, a group of engineers recognized the need for new and improved methods of pumping insulin and incorporated as Phluid, Inc. In 2007, Kim Blickenstaff joined the organization as President and CEO, bringing his philosophy of using market research as the inspiration for product development and started on the development of the t:slim Insulin Pump. In 2008, this predecessor company became the newly incorporated Tandem Diabetes Care, Inc. that was formed with a focus on promoting a comprehensive, user-centric, and integrated approach to diabetes product development and customer care. Tandem Diabetes Care felt that incorporating enhanced ease of use and attractive design—often associated with consumer electronics development—would also encourage more patients to consider the clinical benefits of insulin pump therapy. Tandem Diabetes Care interviewed more than 4,000 insulin pump users and health care providers to design its first device, the t:slim Insulin Pump.

In 2016, the company was ranked #39 on the Deloitte Fast 500 North America list.

In November 2011, the company received FDA clearance to market the t:slim Insulin Pump, the first ever touch-screen insulin pump. In February 2013, the company received FDA clearance to market the t:connect Diabetes Management Application, a Mac and PC-compatible data management application that provides t:slim Pump users and their healthcare providers a way to display data from the pump and supported blood glucose meters on a cloud-based platform. In January 2015, Tandem announced FDA clearance of the t:flex Insulin Pump, the largest capacity insulin pump on the market. In July 2014, Tandem announced that it had submitted a PMA for the t:slim G4, which integrates t:slim Pump technology with the Dexcom G4 Platinum CGM System. This device was approved by the FDA in September 2015. The FDA approved a tool to update the software on Tandem's pumps in July, 2016. The Tandem Product Updater is designed to deliver software updates to Tandem's pumps to provide new features and interface improvements. In announcing the approval, Tandem stated that the first use of the new tool will be to update t:slim pumps which were shipped prior to April, 2015 with a new version of the firmware which speeds the loading process and offers other enhancements. In late October 2016, Tandem began shipping its next-generation pump platform, the t:slim X2. The X2 will receive updates via the Tandem Product Updater product, with planned updates initially including integration with Dexcom's G5 and G6 Continuous Glucose Monitors, and eventually the integration of closed-loop technology which Tandem licensed from TypeZero in July 2016.


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2022 2022-11-04 Future report Set alerts
Q1 2022 2022-05-04 -0.23 -0.23
Q4 2021 2022-02-22 0.16 0.16
Q3 2021 2021-11-03 0.09 0.09
Q2 2021 2021-08-04 0.06 0.06
Q1 2021 2021-05-05 -0.08 -0.08
Q4 2020 2021-02-24 0.22 0.22
Q3 2020 2020-11-05 0.00 0.00
Q2 2020 2020-07-30 -0.45 -0.45
Q1 2020 2020-04-30 -0.25 -0.25

Ratings

2016-06-15 Reiterated Rating Wedbush Outperform $20.00
2016-05-16 Reiterated Rating Sterne Agee CRT Neutral
2016-05-02 Reiterated Rating Robert W. Baird Buy
2016-04-21 Reiterated Rating Piper Jaffray Buy $12.00
2016-04-21 Reiterated Rating Piper Jaffray Cos. Buy $12.00
2016-03-24 Downgrade Bank of America Neutral to Underperform
2016-03-24 Downgrade Bank of America Corp. Neutral to Underperform
2016-01-14 Downgrade Bank of America Buy to Neutral
2016-01-07 Boost Price Target Cowen and Company $15.00
2015-10-30 Boost Price Target Cowen and Company $10.00 to $11.00
2015-10-30 Lower Price Target Robert W. Baird $15.00 to $13.00
2015-10-30 Reiterated Rating Deutsche Bank Buy $19.00 to $17.00
2015-10-30 Reiterated Rating Deutsche Bank AG Buy $19.00 to $17.00
2015-10-21 Reiterated Rating William Blair Market Perform
2015-09-11 Reiterated Rating William Blair Market Perform
2015-08-10 Lower Price Target Deutsche Bank Buy $21.00 to $19.00
2015-07-08 Initiated Coverage Robert W. Baird Outperform $15.00
2015-05-05 Boost Price Target Deutsche Bank Buy $19.00 to $21.00
2015-01-26 Downgrade William Blair Outperform to Market Perform
2014-12-08 Initiated Coverage Cowen and Company Outperform $16.00
2014-11-04 Initiated Coverage Northcoast Research Buy
2014-10-27 Initiated Coverage Wedbush Outperform $20.00
2014-09-04 Initiated Coverage Feltl & Co. Strong-Buy
2014-08-01 Upgrade Bank of America Neutral to Buy
2014-08-01 Reiterated Rating Deutsche Bank Buy $25.00
2014-07-16 Initiated William Blair Outperform
2014-07-15 Initiated Coverage William Blair Outperform $2.00
2014-05-14 Upgrade Deutsche Bank Hold to Buy $28.00 to $25.00
2014-03-20 Initiated Coverage Sterne Agee CRT Neutral $26.00
2013-12-09 Initiated Coverage Bank of America Neutral $27.00
2013-12-09 Initiated Coverage Stifel Nicolaus Buy $30.00
2013-12-09 Initiated Coverage Deutsche Bank Hold $26.00
2013-12-09 Initiated Coverage Piper Jaffray Overweight
2016-06-15 Reiterated Rating Wedbush Outperform $20.00
2016-05-16 Reiterated Rating Sterne Agee CRT Neutral
2016-05-02 Reiterated Rating Robert W. Baird Buy
2016-04-21 Reiterated Rating Piper Jaffray Buy $12.00
2016-04-21 Reiterated Rating Piper Jaffray Cos. Buy $12.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
DOMAIN PARTERS VII L P 13.59%  (3189058) AKAO / CADX / CLVS / ESPR / EVOK / OREX / RGDO / TNDM / ZGNX /
TPG Group Holdings (SBS) Advisors, Inc. 10.64%  (2496194) AERI / ALDR / CDNA / CZR / EPRS / FSL / GPK / IMS / LPLA / MGNX / NCLH / NTI / OTIC / PKY / Q / ROKA / SABR / SCAI / SUP / TIPT / TMHC / TNDM / VCYT / ZMH /
CAHILL EDWARD L 7.41%  (1739154) MASI / TNDM /
HLM VENTURE PARTNERS II, L.P. 6.20%  (1454058) TNDM /
BLICKENSTAFF KIM D PRESIDENT AND CEO 5.92%  (1389750) MDVN / TNDM /
SMITH LONNIE M 0.64%  (149200) ISRG / TNDM /
GREENE HOWARD E JR 0.50%  (117865) TNDM /
VITULLO NICOLE 0.23%  (54390) ACHN / AKAO / CADX / CLVS / CPXX / DRNA / DRTX / ESPR / EVOK / MRNS / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
Halak Brian K 0.23%  (54390) ACHN / AKAO / ALIM / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / TNDM / VCYT / VNDA / ZGNX /
TREU JESSE I 0.23%  (54390) ACHN / AKAO / ALDX / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
DP VII ASSOCIATES LP 0.23%  (54390) AKAO / CADX / CLVS / ESPR / EVOK / OREX / TNDM / ZGNX /
BLAIR JAMES C 0.23%  (54390) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
DOVEY BRIAN H 0.23%  (54390) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / OTIC / RGDO / TNDM / VCYT / ZGNX /
SCHOEMAKER KATHLEEN K 0.23%  (54390) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
Delphi Management Partners VIII, L.L.C. 0.15%  (35467) BAXS / TNDM /
Sheridan John F EXECUTIVE VP AND COO 0.10%  (22763) TNDM /
Allen Dick 0.09%  (22001) TNDM /
TWOMEY CHRISTOPHER J 0.07%  (17572) CADX / SNMX / TNDM /
ROEDER DOUGLAS A 0.06%  (13217) TNDM /
Morrison Susan CAO 0.03%  (8209) TNDM /
BERGER DAVID B GENERAL COUNSEL 0.02%  (4330) SNMX / TNDM /
Anacone Robert EXECUTIVE VP AND CCO 0.01%  (2811) TNDM /
Cajigas John CHIEF FINANCIAL OFFICER 0.01%  (2691) TNDM /